Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis
Thierry Façon, Shaji Kumar, Robert Z. Orlowski, Nizar J. Bahlis et autres
0 citationsLeukemia
Margaret Macro
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
261Publications signalées
13972Citations signalées
2Affiliations récentes
Institutions déclarées
Domaines associés
Multiple Myeloma Research and TreatmentsProtein Degradation and InhibitorsCancer Treatment and PharmacologyPeptidase Inhibition and AnalysisChronic Lymphocytic Leukemia Research
Publications récentes
Response profile and long-term outcomes in Cyclin D1-overexpressing multiple myeloma: insights from the CASSIOPEIA trial
Aurore Perrot, Cyrille Touzeau, Stéphane Minvielle, Cyrille Hulin et autres
0 citationsBlood Cancer Journal
Patient-Centered Education Through A Massive Open Online Course (MOOC) for Patients With Multiple Myeloma and Caregivers: Descriptive Study of Knowledge Gains by French Association of Patients With Multiple Myeloma (AF3M) and French-Speaking Myeloma Intergroup (IFM)
Alexis Talbot, Bernard Delcour, Laurent Gillot, Bertrand Arnulf et autres
0 citationsJMIR Formative Research
35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience
Philippe Moreau, Cyrille Hulin, Alexis Talbot, Hélène Demarquette et autres
3 citationsBlood Cancer Journal
Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma: Results from ISASOCUT (IFM 2022–05)
Arthur Bobin, Anaïs Schavgoulidze, Stéphanie Ragot, Christophe Roul et autres
2 citationsClinical Lymphoma Myeloma & Leukemia
Daratumumab(Dara) Lenalidomide(R) Maintenance Following Dara-Carfilzomib(K)R Dexamethasone with Tandem Transplant in High-Risk Newly Diagnosed Myeloma Patients: Update of the Phase 2 Study IFM 2018-04
Bénédicte Piron, Aurore Perrot, Cyrille Hulin, Salomon Manier et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
Assessing the benefit of incorporating an anti-CD38 monoclonal antibody into second- or third-line systemic treatment for patients with relapsed/refractory multiple myeloma: results from the French real-world EMMY study
Thomas Chalopin, Cyrille Hulin, Bruno Royer, Jean Bastié et autres
0 citationsHaematologica
Real-World Utilization of Carfilzomib (Once or Twice Weekly) Initiated in Patients After a First Relapse Between 2017 and 2022 in France: An Analysis From a Large-Scale Epidemiology of Multiple MYeloma (EmmY) Cohort
Cyrille Hulin, Karim Belhadj Merzoug, Bruno Royer, Denis Caillot et autres
1 citationClinical Lymphoma Myeloma & Leukemia
A Patient-Centered education through Massive Open Online Course (MOOC) for Multiple Myeloma: A Descriptive Study of Knowledge Gains by AF3M and IFM (Preprint)
Alexis Talbot, Bernard Delcour, Laurent Gillot, Bertrand Arnulf et autres
0 citations
The Impact of Anti-CD38 Monoclonal Antibodies in Frontline Therapy for Patients With Newly Diagnosed Multiple Myeloma: Real-Life Results From the EMMY Study
Thomas Chalopin, Olivier Decaux, Cyrille Hulin, Aurore Perrot et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of BENEFIT trial
Émilie Chalayer, Corinne Frère, Élisabeth Daguenet, Thomas Lecompte et autres
4 citationsJournal of Thrombosis and Haemostasis
Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results
Jill Corre, Laure Vincent, Philippe Moreau, Benjamin Hébraud et autres
24 citationsBlood
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.